Results of initial testing of an important new technology to be presented this week at ‘8th World Biomaterials Congress’, Amsterdam

“Our demonstration of the self-assembly of an effective antimicrobial agent bonded to a polymer before device fabrication provides a low-cost alternative to biocidal coatings for reducing device-related infections.” -Robert S. (Bob) Ward, CEO, Polymer Technology Group (PTG)

BERKELEY, Calif. (Business Wire EON/PRWEB ) May 27, 2008 -- The Polymer Technology Group, Inc. (www.polymertech.com), a preeminent biomaterials company, announced today that Shanger Wang, Ph.D., will report from the podium this week during the ‘8th World Biomaterials Congress’ in Amsterdam, The Netherlands. His presentation (“Thermoplastic Polycarbonate-Urethane with Surface-Active Alkylammonium Chloride End Groups: Antimicrobial Activity, Bulk and Surface Properties”) will include the characterization of a breakthrough polymeric biomaterial with permanently-bonded antimicrobial surface properties designed to reduce medical device-centered infection. PTG is also exhibiting at the conference (booth #5).

Our demonstration of the self-assembly of an effective antimicrobial agent bonded to a polymer before device fabrication provides a low-cost alternative to biocidal coatings for reducing device-related infections.

Thermoplastic Polycarbonate-Urethane with Surface-Active Alkylammonium Chloride End Groups: Antimicrobial Activity, Bulk and Surface Properties

Indeed, the results being presented by Dr. Wang demonstrate that very small amounts of biologically active end-groups can be permanently incorporated into a polymeric biomaterial during its synthesis

The novelty here is that after extrusion or molding, the device 'modifies its own surface' because of the surface activity and self assembly of the novel end-groups. Antimicrobial groups concentrate in the surface where they are needed. For this reason secondary coating processes or treatments are not needed. This can reduce the cost of goods and manufacturing times while increasing yield.

“The device industry has been challenged to produce polymeric biomaterials with built-in antimicrobial surface properties for reducing device-centered infection. But most approaches to date have used drug-eluting compounds or coatings that are eventually consumed. It is much more desirable to have easily processed biomaterials with good wet-strength and long-term efficacy without leachable additives, drugs or biocides,” said Bob Ward, CEO. “We believe we have an answer to this problem.

“Indeed, the results being presented by Dr. Wang demonstrate that very small amounts of biologically active end-groups can be permanently incorporated into a polymeric biomaterial during its synthesis,” added Ward. “The novelty here is that after extrusion or molding, the device ‘modifies its own surface’ because of the surface activity and self assembly of the novel end-groups. Antimicrobial groups concentrate in the surface where they are needed. For this reason secondary coating processes or treatments are not needed. This can reduce the cost of goods and manufacturing times while increasing yield.”

Dr. Wang will report that polyurethanes with surface-active alkylammonium chloride end-groups were successfully synthesized and their physical properties, surface chemistry and biocidal activities evaluated. The presence and self assembly of end-groups in the surface was confirmed by SFG (Sum Frequency Generation Spectroscopy). The polymers exhibit low water absorption, excellent strength and processability, high molecular weight, and effective contact-killing of Gram-positive bacteria relative to controls. Dr. Wang will also discuss how these modified TPCUs (Thermoplastic PolyCarbonate Urethanes) and polymers with other antimicrobial ‘self-assembling monomer end groups’ are currently being optimized by PTG for use in various biomedical applications.

ABOUT PTG

Headquartered in Berkeley, Calif., The Polymer Technology Group, Inc. (PTG) specializes in the research, development, design, scale-up, and manufacture of new polymers, medical devices, and components. PTG's recently expanded operations to 70,000-square-feet comprise the equipment and expertise to support production-scale polymer synthesis through contract medical device manufacturing. On April 28th the company announced it has agreed to be acquired by DSM, the global Life Sciences and Materials Sciences company headquartered in the Netherlands. The union with PTG will enable DSM Biomedical to expand its unique portfolio of materials-based technologies which will benefit customers in the medical device and pharmaceutical industries. Closing of the acquisition is expected to take place by the end of May, 2008.

Post Comment:
Trackback URL: http://www.prweb.com/pingpr.php/Q291cC1Db3VwLUZhbHUtRmFsdS1DcmFzLVplcm8=

polymer technology group medical device emergence 8th world biomaterials congress biopolymers biomaterial antimicrobial agents

Bookmark -  Del.icio.us | Furl It | Technorati | Ask | MyWeb | Propeller | Live Bookmarks | Newsvine | TailRank | Reddit | Slashdot | Digg | Stumbleupon | Google Bookmarks | Sphere | Blink It | Spurl